Back to Report Store Home

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics

  • Published: Jun-2016
  • Report Code: GBIHC412MR
  • Report Format: pdf

Description

List of Tables

Table 1: Urologic Oncology, Global, Symptoms of the Most Prevalent Urological Cancers, 2016 10

Table 2: Urologic Oncology, Global, Complications Associated with Bladder, Kidney, Prostate and Testicular Cancers 13

Table 3: Urologic Oncology, Global, Epidemiology of The Most Prevalent Urological Cancers, 2015 14

Table 4: Urologic Oncology, Optimal and Actual Chemotherapy Usage Rates Across All Cancer Stages, 2010 20

Table 5: Urologic Oncology, Global, Reconstructive Surgery following Bladder Cancer Resection, 2016 21

Table 6: Urologic Oncology, Optimal and Actual Radiation Therapy Usage Rates in US, 1995–2000 22

Table 7: Urologic Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2016 26

Table 8: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2016 27

Table 9: Urologic Oncology Therapeutics Market, Global, Approved Indications for Sutent, 2016 29

Table 10: Urologic Oncology Therapeutics Market, Global, Approved Indications for Votrient, 2016 30

Table 11: Urologic Oncology Therapeutics Market, Global, Approved Indications for Inlyta, 2016 31

Table 12: Urologic Oncology Therapeutics Market, Global, Approved Indications for Jevtana, 2016 32

Table 13: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xofigo, 2016 33

Table 14: Urologic Oncology Therapeutics Market, Global, Approved Indications for Provenge, 2016 34

Table 15: Urologic Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2016 36

Table 16: Urologic Oncology, Global, Usage of Generics Across Key Indications, 2016 77

Table 17: Urologic Oncology, Global, Licensing Deals Valued Above $100m, 2006–2016 104

Table 18: Urologic Oncology, Global, Co-development Deals Valued Above $100m, 2006–2016 110

Table 19: Oncology, Global, All Clinical Trial Stage Pipeline Products, 2016 127

Table 20: Abbreviations 145

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards